ACT001 improves OVX-induced osteoporosis by suppressing the NF-κB/NLRP3 signaling pathway

Abstract Osteoporosis (OP) is a common systemic metabolic bone disease characterized by the decrease in bone mass and hyperactivity of osteoclasts. ACT001 is approved as an orphan drug by FDA and has shown multiple protective effects against tissue injury. However, its role in prevention of osteocla...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yuan Li, Jin-Yu Yang, Ma-Li Lin, Tian-Zhu Liu, Wen-Na Lu, Ying Yang, Zhong-Cheng Liu, Jian-Heng Li, Guo-Qiang Zhang, Jian-Shuang Guo
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-04-01
Col·lecció:	Molecular Medicine
Matèries:	ACT001 Osteoporosis Osteoclastogenesis NF-κB pathway NLRP3 inflammasome
Accés en línia:	https://doi.org/10.1186/s10020-025-01189-3
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!